Sandoz has formed an exclusive global alliance with Biocon to co-develop and market “next-generation biosimilars” in the immunology and oncology arenas. Neither the number nor the identity of the targeted molecules have been disclosed, but Biocon said the partnership covered “multi-billion dollar opportunities” through molecules in “early stages of development”. The partners will “share responsibility for end-to-end development, manufacturing, and global regulatory approvals”, and will split costs and profits from marketing the biosimilars equally.
Sandoz and Biocon strike global biosimilars alliance
Sandoz has formed an exclusive global alliance with Biocon to co-develop and market “next-generation biosimilars” in the immunology and oncology arenas. Neither the number nor the identity of the targeted molecules have been disclosed, but Biocon said the partnership covered “multi-billion dollar opportunities” through molecules in “early stages of development”. The partners will “share responsibility for end-to-end development, manufacturing, and global regulatory approvals”, and will split costs and profits from marketing the biosimilars equally.